The National Institute for Health and Care Excellence

Better data for better decisions

Sophie Cooper, Senior Scientific Adviser, explains the importance of the recently published EQ-5D-5L value set and how it has ...
National Institute for Health and Care Excellence

In consultation: Guidance and quality standards

Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer ID6589 Consultation on suggested remit, draft scope and provisional ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over TA1140 17 March 2026 17 March 2026 ...
National Institute for Health and Care Excellence

Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

There is a commercial access agreement for dupilumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess@sanofi.com ...
National Institute for Health and Care Excellence

Published: Indicators

The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer TA1138 2 March 2026 2 March 2026 ...
National Institute for Health and Care Excellence

Suspected sepsis: recognition, diagnosis and early management

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...
National Institute for Health and Care Excellence

Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

Isatuximab, plus pomalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults who have had ...
National Institute for Health and Care Excellence

Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues

We have moved interventional procedures guidance 666 to become HealthTech guidance 535. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...
National Institute for Health and Care Excellence

Impetigo: antimicrobial prescribing

This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic ...